Squarepoint Ops LLC Sells 25,151 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Squarepoint Ops LLC decreased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 34.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 48,374 shares of the company’s stock after selling 25,151 shares during the quarter. Squarepoint Ops LLC owned about 0.07% of Kymera Therapeutics worth $1,946,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Wellington Management Group LLP increased its position in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after purchasing an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after buying an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new stake in shares of Kymera Therapeutics in the 4th quarter worth about $23,856,000. Boxer Capital Management LLC purchased a new stake in shares of Kymera Therapeutics during the 4th quarter valued at about $17,098,000. Finally, Janus Henderson Group PLC grew its position in Kymera Therapeutics by 2,397.9% in the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock worth $15,197,000 after acquiring an additional 362,276 shares in the last quarter.

Kymera Therapeutics Stock Performance

KYMR stock opened at $33.70 on Tuesday. The firm has a 50-day simple moving average of $36.72 and a two-hundred day simple moving average of $42.18. Kymera Therapeutics, Inc. has a one year low of $29.07 and a one year high of $53.27. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -14.40 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

KYMR has been the subject of several analyst reports. BTIG Research started coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Citigroup started coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective on the stock. HC Wainwright raised their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective on the stock. Finally, Leerink Partners reiterated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,788 shares of company stock valued at $455,202. 15.82% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.